Acuta Capital Partners, LLC Portfolio Holdings

Acuta Capital Partners, LLC

  • $53.1 Million
  • Q3 2025

Acuta Capital Partners, LLC has filed its 13F form on November 14, 2025 for Q3 2025 where it was disclosed a total value porftolio of $53.1 Million distributed in 28 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Ocular Therapeutix, Inc with a value of $13.6M, Aadi Bioscience, Inc. with a value of $5.83M, Insmed Inc with a value of $5.56M, Argenx Se with a value of $4.7M, and Amylyx Pharmaceuticals, Inc. with a value of $4.53M.

Examining the 13F form we can see an increase of $12.9M in the current position value, from $40.2M to 53.1M.

Acuta Capital Partners, LLC is based out at Belmont, CA

Below you can find more details about Acuta Capital Partners, LLC portfolio as well as his latest detailed transactions.

Portfolio value $53.1 Million
Healthcare: $53.1 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$875M
$13.6 Million 25.65% of portfolio
1,165,206
Q3 2025 Added 14.81%
$35.9M
$5.83 Million 10.98% of portfolio
3,410,402
Q1 2025 Added 84.41%
$26.2B
$5.56 Million 10.47% of portfolio
38,592
Q3 2025 Added 4.11%
$50.2B
$4.7 Million 8.86% of portfolio
6,379
Q3 2025 Reduced 4.82%
$743M
$4.53 Million 8.53% of portfolio
333,258
Q3 2025 New
$846M
$3.82 Million 7.2% of portfolio
502,797
Q3 2025 Added 8.39%
$8.84B
$3.31 Million 6.23% of portfolio
25,114
Q3 2025 Reduced 4.45%
$494M
$3.15 Million 5.93% of portfolio
840,090
Q3 2025 New
$11.4B
$1.95 Million 3.67% of portfolio
9,792
Q3 2025 Reduced 56.63%
$5.29B
$1.87 Million 3.51% of portfolio
10,573
Q3 2025 New
$2.21B
$1.48 Million 2.78% of portfolio
102,907
Q3 2025 New
$204M
$1.43 Million 2.7% of portfolio
454,827
Q3 2025 Reduced 6.35%
$21.2B
$962,000 1.81% of portfolio
2,296
Q3 2025 New
$451M
$498,000 0.94% of portfolio
57,141
Q3 2025 Reduced 4.21%
$5.94B
$392,000 0.74% of portfolio
8,411
Q3 2025 Reduced 84.9%
Tourmaline Bio Inc
-
$0 0.0% of portfolio
-
Q3 2025 Reduced 5.37%
Surrozen Inc
-
$0 0.0% of portfolio
-
Q3 2025 Added 4.95%
Unicycive Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2025 Reduced 4.63%
Praxis Precision Medicines I
-
$0 0.0% of portfolio
-
Q3 2025 Reduced 32.85%
Oculis Holding Ag
-
$0 0.0% of portfolio
-
Q3 2025 Reduced 4.63%
-
$0 0.0% of portfolio
-
Q2 2022 New
Lb Pharmaceuticals Inc
-
$0 0.0% of portfolio
-
Q3 2025 New
Inhibrx Biosciences Inc
-
$0 0.0% of portfolio
-
Q3 2025 New
Dianthus Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2025 New
Cidara Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2025 Reduced 21.18%
Bright Minds Biosciences Inc
-
$0 0.0% of portfolio
-
Q3 2025 Added 75.09%
Zymeworks Inc
-
$0 0.0% of portfolio
-
Q3 2025 Reduced 4.2%

Summary

  • Portfolio
  • No. of Stocks 28
  • Current Value $53.1 Million
  • Prior Value $40.2 Million
  • Filing
  • Period Q3 2025
  • Filing Date November 14, 2025
  • Form Type 13F-HR
  • Activity in Q3 2025
  • New Purchases 8 stocks
  • Additional Purchases 5 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 13 stocks
Track This Portfolio

Track Acuta Capital Partners, LLC Portfolio

Follow Acuta Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acuta Capital Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email